On June 13 , the 25th Shanghai International Symposium on Biotechnology and Medicine hosted by Shanghai Biomedical Science and Technology Development Center kicked off at the Shanghai International Convention Center. The theme of this year's conference is "Give full play to the advantages of innovation sources and create an economic highland for R&D".
The conference attracted more than 200 domestic and foreign experts to speak. During the period, " 1+2+3+14 " activities will be held, that is, 1 opening ceremony and keynote speech, 2 closed-door meetings, 3 concurrent activities, and 14 special topics branch.
Gather industry consensus
Helping the innovation and development of biomedicine in Shanghai
Zhu Qigao, deputy director of the Municipal Science and Technology Commission, said at the opening ceremony that in recent years, the Shanghai Municipal Party Committee and the Municipal Government have attached great importance to the innovation and development of biomedical science and technology, focused on the construction of an international science and technology innovation center, conscientiously implemented the "Shanghai Plan" for biomedical highlands, and accelerated the creation of a global biomedical science and technology innovation center. Highland of pharmaceutical R&D economy and industrialization.
Shen Jianzhong, deputy director of the China Biotechnology Development Center, mentioned at the opening ceremony that the cross-integration of biomedical technology innovation and multidisciplinary research is constantly strengthening, which has brought disruptive breakthroughs to the treatment of diseases. He called for joint contributions to the national biomedical industry Innovation contributes.
This year coincides with the 25th anniversary of the forum , and the conference has become a "reservoir" to promote the development of Shanghai's biomedical technology, continuously injecting new innovation momentum into Shanghai's biomedical industry.
After 25 years of careful irrigation, the scale of the forum has grown from small to large, and the voice of the industry has continued to increase. It has become a landmark event in Shanghai's biomedical industry. At this year's opening ceremony, a 25th anniversary awards ceremony was specially set up.
The keynote speeches on that day were presided over by Yu Kangxin, Executive Vice President of Chia Tai Tianqing Pharmaceutical Group Co., Ltd., and Cui Yi, Senior Vice President of Hutchison Whampoa Pharmaceutical (Shanghai) Co., Ltd. At the meeting, Chinese and foreign academicians, experts and presidents of multinational companies gathered, not only looking forward to The macro prospect of innovation and development of biomedicine also discusses the frontier progress and future path of hot areas in a simple way.
Dong Chen, academician of the Chinese Academy of Sciences, focused on T cells and immunotherapy, introduced the process of transforming immunology from basic research to solving clinical problems, and pointed out that new methods can bring new innovative drug results and promote industrial development.
Dr. Jonathan Sadeh , Senior Vice President of Global R&D and Head of Immunology and Fibrosis Drug Development, Bristol-Myers Squibb, a world-leading biopharmaceutical company, and Mr. Maxwell Kirkby, Acting Head of China R&D Department , shared their focus on channels through online and offline linkage. Scientific research and development strategies to address unmet clinical needs in the field of immune-mediated diseases, and emphasized the importance of co-creation with the life science ecosystem in China's research and development.
Wang Junzhi, academician of the Chinese Academy of Engineering, comprehensively reviewed the development of China's biopharmaceuticals and introduced the development of China's vaccine industry. He pointed out that the overall structure of China's vaccines is developing in the direction of originality, high efficiency, high production capacity, and globalization.
Xu Huaqiang, a researcher at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, combined the structural biology research of hormone receptors with the discovery of original drugs, fully reflecting the supporting role of basic research in industrial innovation. He emphasized that cognition is the greatest competitiveness, and drug design needs to be based on the underlying logic of biomedicine and follow the physiological laws of the human body.
Academician of the National Academy of Sciences, the National Academy of Medicine, the National Academy of Engineering, and the National Academy of Inventors, and a professor at MIT, Robert Langer is legendary in the field of industry, education and research. He not only applied for more than 1,400 patents, but also founded many cutting-edge technology companies that were acquired by large companies. , and as an investor with a scientific background, successfully invested in emerging companies such as Moderna . With an asset of US$ 1.8 billion , he is known as the first person in translational research in the world. He introduced the latest progress in the field of targeted drug delivery, which is expected to promote drug delivery to achieve the last mile of efficient treatment in the future.
